Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for lassa fever

Clinical Infectious Diseases

Volumn 51, Issue 12, 2010, Pages 1435-1441

  Bausch, Daniel G ^a   Hadi, Christiane M ^a   Khan, Sheik Humarr ^c   Lertora, Juan J L ^b  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Kenema Government Hospital   (Sierra Leone)

Author keywords

[No Author keywords available]

Indexed keywords

RIBASPHERE; RIBAVIRIN; UNCLASSIFIED DRUG;

AFRICA; DISEASE TRANSMISSION; DRUG EFFICACY; HUMAN; INCUBATION TIME; LASSA FEVER; LASSA VIRUS; LOADING DRUG DOSE; MEDICAL LITERATURE; MORTALITY; NONHUMAN; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTIVIRAL AGENTS; CHEMOPREVENTION; HUMANS; LASSA FEVER; PRACTICE GUIDELINES AS TOPIC; RIBAVIRIN;

EID: 78649851306     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/657315     Document Type: Review

References (85)

1. McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES. A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis 1987; 155:437-444.
2. Monath TP, Newhouse VF, Kemp GE, Setzer HW, Cacciapuoti A. Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. Science 1974; 185:263-265.
3. Enria D, Mills JN, Flick R, et al. Arenavirus Infections. In: Guerrant RL, Walker DH, Weller PF, eds. Tropical infectious diseases: principles, pathogens, and practice. 2nd ed. Vol. 1. Philadelphia, PA: Elsevier, 2006: 734-755.
4. Fisher-Hoch SP, Tomori O, Nasidi A, et al. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. BMJ 1995; 311:857-859.
5. World Health Organization. Update on Lassa fever in West Africa. Wkly Epidemiol Rec 2005; 80:86-88.
6. Carey DE, Kemp GE, White HA, et al. Lassa fever: epidemiological aspects of the 1970 epidemic, Jos, Nigeria. Trans R Soc Trop Med Hyg 1972; 66:402-408.
7. Monath TP, Mertens PE, Patton R, et al. A hospital epidemic of Lassa fever in Zorzor, Liberia, March-April 1972. Am J Trop Med Hyg 1973; 22:773-779.
8. Bausch DG, Rollin PE, Demby AH, et al. Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent-antibody test, and virus isolation. J Clin Microbiol 2000; 38:2670-2677.
9. Drosten C, Kummerer BM, Schmitz H, Gunther S. Molecular diagnostics of viral hemorrhagic fevers. Antiviral Res 2003; 57:61-87. (Pubitemid 36254722)
10. McCormick JB, King IJ, Webb PA, et al. Lassa fever: effective therapy with ribavirin. N Engl J Med 1986; 314:20-26.
11. Barry M, Russi M, Armstrong L, et al. Brief report: treatment of a laboratory- acquired Sabia virus infection. N Engl J Med 1995; 333:294-296.
12. Kilgore PE, Ksiazek TG, Rollin PE, et al. Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clin Infect Dis 1997; 24:718-722.
13. Huggins JW, Hsiang CM, Cosgriff TM, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 1991; 164: 1119-1127.
14. Fisher-Hoch SP, Khan JA, Rehman S, Mirza S, Khurshid M, McCormick JB. Crimean Congo-haemorrhagic fever treated with oral ribavirin. Lancet 1995; 346:472-475.
15. Mardani M, Jahromi MK, Naieni KH, Zeinali M. The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran. Clin Infect Dis 2003; 36:1613-1618. (Pubitemid 36783348)
16. Picardi A, Gentilucci UV, Zardi EM, D'Avola D, Amoroso A, Afeltra A. The role of ribavirin in the combination therapy of hepatitis C virus infection. Curr Pharm Des 2004; 10:2081-2092. (Pubitemid 38842652)
17. Ventre K, Randolph A. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 2004; (4):CD000181.
18. McJunkin JE, Khan R, de los Reyes EC, et al. Treatment of severe La Crosse encephalitis with intravenous ribavirin following diagnosis by brain biopsy. Pediatrics 1997; 99:261-267.
19. Mustafa MM, Weitman SD, Winick NJ, Bellini WJ, Timmons CF, Siegel JD. Subacute measles encephalitis in the young immunocompromised host: report of two cases diagnosed by polymerase chain reaction and treated with ribavirin and review of the literature. Clin Infect Dis 1993; 16:654-660.
20. Uyeki TM. Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza. Pediatr Infect Dis J 2003; 22:164-177.
21. Gavin PJ, Katz BZ. Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children. Pediatrics 2002; 110:e9.
22. Snell NJ. Ribavirin - current status of a broad spectrum antiviral agent. Expert Opin Pharmacother 2001; 2:1317-1324.
23. Crotty S, Cameron CE, Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A 2001; 98:6895-6900. (Pubitemid 32538313)
24. Crotty S, Maag D, Arnold JJ, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000; 6:1375-1379.
25. Cameron CE, Castro C. The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase. Curr Opin Infect Dis 2001; 14:757-764.
26. Tam RC, Lau JY, Hong Z. Mechanisms of action of ribavirin in antiviral therapies. Antivir Chem Chemother 2001; 12:261-272.
27. Patterson JL, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990; 12:1139-1146.
28. Crowcroft NS, Meltzer M, Evans M, et al. The public health response to a case of Lassa fever in London in 2000. J Infect 2004; 48:221-228.
29. Holmes GP, McCormick JB, Trock SC, et al. Lassa fever in the United States: iInvestigation of a case and new guidelines for management. N Engl J Med 1990; 323:1120-1123.
30. Fisher-Hoch SP, Gborie S, Parker L, Huggins J. Unexpected adverse reactions during a clinical trial in rural West Africa. Antiviral Res 1992; 19:139-147.
31. Haas WH, Breuer T, Pfaff G, et al. Imported Lassa fever in Germany: surveillance and management of contact persons. Clin Infect Dis 2003; 36:1254-1258.
32. Chapman LE, Mertz GJ, Peters CJ, et al. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Antivir Ther 1999; 4:211-219.
33. Hillyard IW. The preclinical toxicology and safety of ribavirin. In: Smith W, Kirkpatrick W, eds. Ribavirin: a broad spectrum antiviral agent. New York: Academic Press, 1980:59-71.
34. Japour AJ, Lertora JJ, Meehan PM, et al. A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13:235-246.
35. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26:473-477. (Pubitemid 27328328)
36. Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25:591-598.
37. Tod M, Farcy-Afif M, Stocco J, et al. Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C. Clin Pharmacokinet 2005; 44:417-428. (Pubitemid 40663686)
38. McKee KT Jr, Huggins JW, Trahan CJ, Mahlandt BG. Ribavirin prophylaxis and therapy for experimental Argentine hemorrhagic fever. Antimicrob Agents Chemother 1988; 32:1304-1309.
39. Russmann S, Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem 2006; 13:3351-3357.
40. Canonico PG. Efficacy, toxicology and clinical applications of ribavirin against virulent RNA viral infections. Antiviral Res 1985; (Suppl 1): 75-81.
41. Price ME, Fisher-Hoch SP, Craven RB, McCormick JB. A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy. BMJ 1988; 297:584-587.
42. Frame JD. Clinical features of Lassa fever in Liberia. Rev Infect Dis 1989; 11(Suppl 4):S783-S789.
43. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis 1989; 11(Suppl 4):S750-S761.
44. Huggins JW, Jahrling PB, Kende M, Canonico PG. Efficacy of ribavirin against virulent RNA virus infections. In: Smith RA, Knight V, Smith JAD, eds. Clinical applications of ribavirin. New York: Academic Press, 1984:49-63.
45. Bossi P, Tegnell A, Baka A, et al. Bichat guidelines for the clinical management of haemorrhagic fever viruses and bioterrorism-related haemorrhagic fever viruses. Euro Surveill 2004; 9:E11-E12.
46. Johnson K. Lassa fever: life saving therapy with ribavirin. In: Stapleton T, ed. Studies with broad spectrum antiviral agent. Vol. 108. London: Royal Society of Medicine Services, 1986:25-36.
47. Crowcroft NS. Management of Lassa fever in European countries. Euro Surveill 2002; 7:50-52.
48. Johnson KM, Monath TP. Imported Lassa fever - reexamining the algorithms. N Engl J Med 1990; 323:1139-1141.
49. Cummins D. Lassa fever. Br J Hosp Med 1990; 43:186-188, 190, 192.
50. Centers for Disease Control and Prevention. Management of patients with suspected viral hemorrhagic fever. MMWR Morb Mortal Wkly Rep 1988; 37(Suppl 3):1-16.
51. Fisher-Hoch SP, Price ME, Craven RB, et al. Safe intensive-care management of a severe case of Lassa fever with simple barrier nursing techniques. Lancet 1985; 2:1227-1229.
52. Helmick CG, Webb PA, Scribner CL, Krebs JW, McCormick JB. No evidence for increased risk of Lassa fever infection in hospital staff. Lancet 1986; 2:1202-1205.
53. Frame JD, Baldwin JM Jr, Gocke DJ, Troup JM. Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am J Trop Med Hyg 1970; 19:670-676.
54. McCormick JB, King IJ, Webb PA, et al. A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis 1987; 155: 445-455.
55. Bausch DG, Demby AH, Coulibaly M, et al. Lassa fever in Guinea. I. Epidemiology of human disease and clinical observations. Vector Borne Zoonotic Dis 2001; 1:269-281.
56. Mahanty S, Hutchinson K, Agarwal S, McRae M, Rollin PE, Pulendran B. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 2003; 170:2797-2801. (Pubitemid 36302147)
57. Baize S, Kaplon J, Faure C, Pannetier D, Georges-Courbot MC, Deubel V. Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. J Immunol 2004; 172:2861-2869. (Pubitemid 38263671)
58. Bowen MD, Rollin PE, Ksiazek TG, et al. Genetic diversity among Lassa virus strains. J Virol 2000; 74:6992-7004. (Pubitemid 30470682)
59. Knobloch J, McCormick JB, Webb PA, Dietrich M, Schumacher HH, Dennis E. Clinical observations in 42 patients with Lassa fever. Tropenmed Parasitol 1980; 31:389-398.
60. Monson MH, Frame JD, Jahrling PB, Alexander K. Endemic Lassa fever in Liberia. I. Clinical and epidemiological aspects at Curran Lutheran Hospital, Zorzor, Liberia. Trans R Soc Trop Med Hyg 1984; 78: 549-553.
61. Jahrling PB, Frame JD, Smith SB, Monson MH. Endemic Lassa fever in Liberia. III. Characterization of Lassa virus isolates. Trans R Soc Trop Med Hyg 1985; 79:374-379.
62. Jahrling PB, Hesse RA, Eddy GA, Johnson KM, Callis RT, Stephen EL. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J Infect Dis 1980; 141:580-589. (Pubitemid 10109827)
63. Jahrling PB, Peters CJ, Stephen EL. Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. J Infect Dis 1984; 149:420-427.
64. Stephen EL, Jahrling PB. Experimental Lassa fever virus infection successfully treated with ribavirin. Lancet 1979; 1:268-269.
65. Weissenbacher MC, Calello MA, Merani MS, McCormick JB, Rodriguez M. Therapeutic effect of the antiviral agent ribavirin in Junin virus infection of primates. J Med Virol 1986; 20:261-267.
66. Maiztegui JI, Fernandez NJ, de Damilano AJ. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 1979; 2: 1216-1217.
67. Gunther S, Asper M, Roser C, et al. Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro. Antiviral Res 2004; 63:209-215.
68. Connor J, Hintz M, van Dyke R. Ribavirin pharmacokinetics in children and adults during therapeutic trials. In: Smith R, Knight V, Smith J, eds. Clinical applications of ribavirin. Orlando: Academic Press, 1984:107-123.
69. Andrei G, De Clercq E. Inhibitory effect of selected antiviral compounds on arenavirus replication in vitro. Antiviral Res 1990; 14: 287-299. (Pubitemid 20377566)
70. Rodriguez M, McCormick JB, Weissenbacher MC. Antiviral effect of ribavirin on Junin virus replication in vitro. Rev Argent Microbiol 1986; 18:69-74.
71. Huggins JW, Robins RK, Canonico PG. Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses. Antimicrob Agents Chemother 1984; 26:476-480.
72. Fernandez H, Banks G, Smith R. Ribavirin: a clinical overview. Eur J Epidemiol 1986; 2:1-14.
73. Austin RK, Trefts PE, Hintz M, Connor JD, Kagnoff MF. Sensitive radioimmunoassay for the broad-spectrum antiviral agent ribavirin. Antimicrob Agents Chemother 1983; 24:696-701.
74. Lertora JJ, Rege AB, Lacour JT, et al. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1991; 50:442-449.
75. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999; 19(Suppl 1):17-24.
76. Catlin DH, Smith R, Samuels AI. 14C-ribavirin: distribution and pharmacokinetic studies in rats, baboon and man. In: Smith RA, Kirkpatrick W, eds. Ribavirin: a broad spectrum antiviral agent. New York: Academic Press, 1980:83-98.
77. Preston SL, Drusano GL, Glue P, Nash J, Gupta SK, McNamara P. Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob Agents Chemother 1999; 43:2451-2456.
78. Paroni R, Del Puppo M, Borghi C, Sirtori CR, Galli Kienle M. Pharmacokinetics of ribavirin and urinary excretion of the major metabolite 1,2,4-triazole-3-carboxamide in normal volunteers. Int J Clin Pharmacol Ther Toxicol 1989; 27:302-307.
79. McCormick JB, Fisher-Hoch SP. Lassa fever. Curr Top Microbiol Immunol 2002; 262:75-109.
80. Maeda Y, Kiribayashi Y, Moriya T, et al. Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C. Ther Drug Monit 2004; 26:9-15. (Pubitemid 38140904)
81. Bruchfeld A, Lindahl K, Schvarcz R, Stahle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2002; 24:701-708. (Pubitemid 35379522)
82. Roberts RB, Laskin OL, Laurence J, et al. Ribavirin pharmacodynamics in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther 1987; 42:365-373.
83. Sidwell RW, Robins RK, Hillyard IW. Ribavirin: an antiviral agent. Pharmacol Ther 1979; 6:123-146.
84. Canonico PG, Kende M, Luscri BJ, Huggins JW. In-vivo activity of antivirals against exotic RNA viral infections. J Antimicrob Chemother 1984; 14(Suppl A):27-41.
85. Bausch DG, Sesay SS, Oshin B. On the front lines of Lassa fever: Aniru Conteh (1942-2004). Emerg Infect Dis 2004; 10:1889-1890.